Dr. Kirti Ranjan Mohanty Radiation Oncologist in Hyderabad

Dr. Kirti Ranjan Mohanty

Radiation Oncologist, Hyderabad

MBBS, MD

  • 3 Hospitals

About


  • Languages : English, Hindi, Oriya, Telugu

Specialities

  • Radiation Oncology

Education

MBBS, 2007, SCB Medical College, Cuttack

MD (Radiation Oncology), AHRCC, Cuttack

Practice Information

Yashoda Hospitals, Somajiguda

Yashoda Hospitals, Somajiguda

Rajbhavan Road, Somajiguda, Hyderabad, Telangana - 500082

Apollo Medical Centre, Kondapur

Apollo Medical Centre, Kondapur

Plot No. 2 - 20/6/A, Kothaguda X Roads, Beside Swagth De-Royal Restaurants, Kondapur, Hyderabad, Telangana - 500084

Star Hospitals, Hyderabad

Star Hospitals, Hyderabad

Road. No. 10, 8 - 2 - 596/5, Banjara Hills, Hyderabad, Telangana - 500034

Achievements & Contributions

  • Awarded certificate for INDIAN ASSOCIATION OF PALLIATIVE CARE - 2011 (Second position)
  • Gold medal for MD (Radiation Oncology) – 2013
  • Granulocytic sarcoma of ovary associated with chronic myelogenous leukemia mimicking carcinoma - A rare case report. Journal of Cancer and Tumor International. Dec 2015.
  • A comparative study of the response and toxicities in locally advanced head and neck cancer patients treated with paclitaxel, cisplatinum, 5-FU versus docetaxel, cisplatinum, 5-FU as neoadjuvant chemotherapy followed by concurrent chemoradiation. Journal of Clinical Oncology Sept 2013
  • Primary Granulocytic Sarcoma of Meninges and Mediastinum as Diagnostic Delema - Indian Journal of Hematology & Blood Transfusion. March 2012
  • Presented poster at AROI Kolkata 2012 on - A comparative analysis of response & toxicity of paclitaxel, cisplatin, 5-FU vs docetaxel, cisplatin, 5-FU as neoadjuvant chemotherapy followed by concurrent chemoradiation in locally advanced head & neck cancer.
  • Presented poster at Cancer CI 2013 Hyderabad on - A comparative analysis of response & toxicity of paclitaxel,cisplatin, 5-FU vs docetaxel, cisplatin, 5-FU as neoadjuvant chemotherapy followed by concurrent chemoradiation in locally advanced head & neck cancer.
  • Poster presentation at ASCO 2013 - Chicago, USA on - A comparative analysis of response & toxicity of paclitaxel, cisplatin, 5-FU vs docetaxel, cisplatin, 5-FU as neoadjuvant chemotherapy followed by concurrent chemoradiation in locally advanced head & neck cancer.
  • European Society for Medical Oncology (ESMO)
  • Association of Radiation Oncologist of India (AROI)
  • European Society for Radiotherapy and Oncology (ESTRO)
-->